Impact of Circadian Rhythm on the Spread of Circulating Tumor Cells in Lung Cancer Patients
NCT ID: NCT05988970
Last Updated: 2026-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
27 participants
INTERVENTIONAL
2024-01-29
2026-01-21
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
27 patients will be included in the study and will be followed for 12 months.
For each included patient, blood samples will be collected before the anticancer treatment initiation.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Molecular Profiling and Dynamic Changes of ctDNA in Unresectable Locally Advanced NSCLC
NCT05641870
Exploring Biological Linkage Between Circadian Disruption and Cancer Progression
NCT02011815
Study of Early Cancer Biomarkers in Breath Condensate in Population of Individuals With High-Risk of Lung Cancer Undergoing LDCT Screening.
NCT06016569
Sleep Disorders and Tumor Immune Microenvironment
NCT06941948
Sleep Disturbance in Lung Cancer Patients.
NCT00187980
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patients with Non- Small Cell Lung Cancer - NSCLC
Blood samples will be collected at two times before the treatment initiation:
* at 4:00 a.m.
* at 10:00 a.m.
Patients will then be followed for data collection for a period of 12 months after inclusion or until disease progression (if applicable).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood samples will be collected at two times before the treatment initiation:
* at 4:00 a.m.
* at 10:00 a.m.
Patients will then be followed for data collection for a period of 12 months after inclusion or until disease progression (if applicable).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient aged ≥ 18 years
3. Life expectancy \> 3 months
4. Patient naïve to treatment for NSCLC
5. Patient hospitalized at least one night for initiation of specific treatment (chemotherapy, radiotherapy, surgery, other...)
6. Patient with no other active cancer. Cancer history accepted if more than 3 years old and considered cured.
7. Patient affiliated to a Social Security scheme in France.
8. Patient having signed informed consent prior to inclusion in the study and prior to any specific study procedure.
Exclusion Criteria
2. Patient previously treated for NSCLC
3. Outpatient
4. Patient with active pathology such as sepsis or uncontrolled inflammatory syndrome
5. Any pathology contraindicating the sample collection procedures required by the study.
6. Pregnant or breast-feeding women.
7. Any psychological, family, geographical or sociological condition that makes it impossible to comply with the medical follow-up and/or procedures stipulated in the study protocol.
8. Patients deprived of their liberty or under legal protection (guardianship, legal protection).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Institut Claudius Regaud
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Larrey
Toulouse, , France
Institut Universitaire du Cancer de Toulouse - Oncopole
Toulouse, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
23 POUM 02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.